Oxgene, a biotechnology company designing and developing scalable gene therapy technologies, has launched its scalable, plasmid-free manufacturing system for AAV. The new TESSA technology addresses industry-wide challenges associated with robust and reproducible AAV manufacture at scale, according to Oxgene. These include high cost of goods, and low packaging efficiency. TESSA aims to deliver a paradigm shift in scalable AAV manufacture.   Adeno-associated virus, or AAV, is a popular choice of v...